Compare Lufax Holding Ltd (LU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Novo Nordisk A/S — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 168.2× Lufax Holding Ltd's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Novo Nordisk A/S for 116 Days on average.
| LU | NVO | |
|---|---|---|
Market Cap | $982.89M | $165.31B |
Volume | 3,323,384 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $3.78 | $63.98 |
52-Week Low | $0.95 | $35.29 |
Typical Hold Time | 13 Days | 116 Days |
Enterprise Value | $58.81B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.95, down 3.54% on the day, with a bearish technical signal from moving averages but a bullish oscillator reading. The company reported a net loss of $2.10 billion in 2025 on revenue of $23.11 billion, with negative net income margins and ROE. A 10:1 reverse stock split occurred on October 23, 2026, and recent news highlights regulatory challenges and balance sheet strength.
The outlook remains challenged by persistent losses and revenue declines, though deep value is suggested by a P/B of 0.07 and strong parent backing. Risks include regulatory tightening in China and elevated credit costs, but analyst consensus is 69% buy with potential catalysts from capital return events.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
